FDA Selects Ingenix for Drug Safety Monitoring and Support
Posted on: Wednesday, 28 September 2005, 18:01 CDT
UnitedHealth Group (NYSE:UNH):
-- New Technology to Help Accelerate Identification of Drug Safety Signals
Ingenix, a wholly owned subsidiary of UnitedHealth Group (NYSE:UNH), has been selected by the United States Food and Drug Administration (FDA) to help improve the effectiveness and speed of safety evaluations for pharmaceutical agents. The Ingenix program is built around a team of leading epidemiologists, complex analytic tools, and the largest and most complete longitudinal patient database available today. It will work with the FDA to monitor the safety of new drugs as well as conduct ad hoc safety studies on established pharmaceutical agents.
"We are pleased to provide our extensive data resources and analytic capabilities to help the FDA respond to the urgent need for improved drug safety," said Terri Madison, PhD, MPH, president of i3 Drug Safety which will lead the Ingenix program. "These proactive efforts should enhance the FDA's ability to identify and assess issues and potential risks related to pharmaceutical agents in a more timely fashion than ever before."
About Ingenix
A leading health information company, Ingenix provides products and services to a diverse customer base within the health care community. Organizations rely on its innovative technology to improve the delivery and operations of their business. More information about Ingenix and its products and services can be obtained at www.ingenix.com.
About i3
i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout pharmaceutical product lifecycle. It includes: i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, which is engaged in pharmacovigilance and epidemiology; i3 Statprobe, a technologically focused provider of comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; i3 Magnifi, which provides health economics and outcomes services; and i3 DLN, a provider of certified medical education. i3 helps companies gain sharper insights that lead to improved patient care. For more information, visit www.i3global.com.
Source: Business Wire
Related Articles
- House to Home Services is Selected as a Unique Health Provider
- Oncology Group's Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program
- Quest Diagnostics to Support Walgreens and Take Care Health Systems' Offer of Free Health Services by Providing Certain Free Laboratory Testing
- Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider
- European Patient Safety and Parallel Pharmaceutical Trade - A Potential Public Health Disaster?
- Camargo Pharmaceutical Services Announces Education Series on FDA 505(B)(2) Approval Route
- EXP Pharmaceutical Services to Be Featured on Alexander Haig's Health Journal Television Series, January 14, 2007 on CNBC (As Paid Programming)
- Research & Markets: Caremark Rx, Inc, One of the Leading Pharmaceutical Services Companies Provides Prescription Benefit Management Services to Over 2,000 Health Plans
- Alliance Systems, tekVizion Sign Joint Services Agreement; Duo to Help Streamline Service Providers' Transition to Reliable VoIP Networks
 |
 |
User Comments (0)
RSS Feeds